Titan Spine has obtained the US Food and Drug Administration’s (FDA) approval to commercially launch its Endoskeleton TL system for lateral spinal fusion.


According to Titan Spine, Endoskeleton TL is the first application of the company’s proprietary roughened titanium surface technology to the lateral approach.

The roughened titanium surface technology has been shown to upregulate the production of osteogenic and angiogenic factors that are critical for bone growth and fusion.

The Endoskeleton TL system features large windows and large internal volumes to allow for bone graft packing, clear CT and MRI imaging, desired bone graft loading, and the ability to pack additional bone graft material within the device following implantation.

First surgeries using the Endoskeleton TL has been performed by Salt Lake Orthopaedic Clinic orthopedic spine surgeon Dr Kade Huntsman at St. Mark’s Hospital in Salt Lake City in July 2014.

Titan Spine chief medical officer Dr Paul Slosar said that the ability to orchestrate cellular behavior and promote bone growth in response to an interbody device has not been in the lateral surgeon’s armamentarium until now.

"The TL is the byproduct of a unique collaboration between academic biomaterial scientists, spine surgeons, and industry experts to create a truly differentiated lateral interbody device that is designed to benefit both patients and surgeons," Dr Slosar added.

"With the addition of the TL device, Titan Spine now offers its surface technology and complete line of titanium devices for virtually all interbody fusion spine surgery procedures in the cervical and lumbar spine."

Image: Titan Spine’s Endoskeleton TL system for lateral spinal fusion. Photo: Courtesy of Business Wire/ Titan Spine, LLC